Dong-A ST to Present Preclinical Results of SHP1 Allosteric Inhibitor and Immunotherapy Agent at AACR 2024
Panoramic view of Donga ST [메디칼업저버 신형주 기자] Dong-A ST will present a poster on the preclinical results of his SHP1 allosteric inhibitor and immunotherapy agent DA-4511 at the American Association for Cancer Research (AACR 2024) held in San Diego, California from the 5th to the 10th. Dong-A ST plans to present a poster on […]
Pharmaceutical Industry Trends at AACR 2024: New Anticancer Drug Research Revealed
[메디칼업저버 신형주 기자] With the AACR due to take place next month, where early research and pre-clinical stage information in the anticancer field will be published to provide insight into the future of anticancer drugs, attention is paid to industry submission trends domestic pharmaceuticals. The annual conference of the American Association for Cancer Research 2024 […]
Dong-A ST Target Stock Price Soars as Sales of Prescription Drugs and Overseas Division Rise
[비즈니스포스트] The target stock price of Dong-A ST (Dong-A ST) has increased. Profitability is expected to be strengthened this year as sales of prescription drugs and overseas divisions continue to increase. ▲ Shinyoung Securities raised its target stock price for Dong-A ST (pictured) on the 16th, saying its profitability will strengthen in 2024 thanks to […]
Hugel’s Love Brick Sharing Event Enters 12th Year
◆Hugel is hosting a ‘Love Brick Sharing Event’ for the 12th year Hugel’s ‘Coal Sharing Love Event’ (Photo = Hugel) Hugel announced on the 2nd that he is holding a ‘Love Brick Sharing Event’ in Chuncheon, Gangwon Special Self-Governing Province. The Love Coal Sharing Event is Hugel’s representative social contribution activity that has been going […]
Dong-A ST Acquires AbTis and Begins Development of New Antibody Drug Combination
Panoramic view of Donga ST [메디칼업저버 신형주 기자] Dong-A ST begins full-scale development of a new antibody drug combination (ADC), which is attracting the most attention in the global pharmaceutical market. Dong-A ST announced on the 20th that it has acquired AbTis, a company specializing in ADC. Dong-A ST acquired the management rights of Aptis […]
Donga ST and Hallym Pharmaceuticals Sign Business Agreement for Export of Eye Drops and New Drugs
Donga ST and Hallym Pharmaceuticals Sign Agreement for Export of Eye Drops and New Drug Enhancement The headquarters of Donga ST in Yongdu-dong, Dongdaemun-gu, Seoul, witnessed a significant meeting on the 17th. Donga ST’s CEO, Kim Min-young, and Hallym Pharmaceuticals’ CEOs, Kim Jae-yoon and Kim Jeong-jin, announced on the 18th that they have officially signed […]
HK InnoN and Dong-A ST Collaborate to Develop Treatment for Non-Small Cell Lung Cancer
HK InnoN Signs Joint Research Agreement with Dong-A ST to Develop Lung Cancer Treatment HK InnoN, a leading biotechnology company, has recently announced its partnership with Dong-A ST for the development of a groundbreaking treatment for non-small cell lung cancer. This joint research agreement aims to combine HK InnoN’s expertise in EGFR inhibitors with Dong-A […]
Daewoong Bio Expands Antibiotics Business with New Plant Investment
Daewoong Bio to Expand Antibiotics Business, Investing 50 Billion Won in New Plant Daewoong Bio has announced plans to expand its antibiotics business, with a goal to reach a scale of 100 billion won. The company has recently decided to invest 50 billion won in building a new plant dedicated to producing ‘Cefarosporin (Cepha)’ antibiotics. […]
Dong-A Socio Group Launches Digital Healthcare Business Promotion Team
Launch of Digital Healthcare Business Promotion Team A ceremony was held at Dong-A Socio Group headquarters to mark the official launch of the ‘Digital Healthcare Business Promotion Team’. This move signifies Dong-A Socio Group’s expansion into the digital healthcare field. On the 11th of this month, Dong-A Socio Group held an inauguration ceremony, attended by […]
New Anti-Obesity Drug ‘DA-1726’ Shows Promising Weight Loss Effects, Presented at ADA Conference
Dong-A ST and Neurobo Pharmaceuticals made a groundbreaking announcement at the 83rd American Diabetes Association (ADA) conference regarding their new anti-obesity drug, ‘DA-1726.’ This prestigious international event, held at the San Diego Convention Center, provided the perfect platform for the companies to present the weight loss effects of the drug. The research findings were unveiled […]
